Biokin Pharmaceutical

Biokin Pharmaceutical focuses on the frontiers of global biopharmaceuticals, addressing unmet clinical needs. The company possesses globally leading innovative R&D capabilities in the field of tumor macromolecule therapeutics (ADC/GNC/ARC), as well as global clinical development and large-scale production and supply capabilities, gradually evolving into a comprehensive biopharmaceutical enterprise with global commercialization capabilities. Adhering to the strategic positioning of “Rooted in China, Going Global, Becoming a Multinational Corporation (MNC),” Biokin Pharmaceutical is committed to becoming an MNC with a globally leading advantage in oncology medications. The company operates R&D centers in both China and the United States, namely the SystImmune R&D Center in Seattle, USA, and the Biokin Pharmaceutical R&D Center and Duote Bio R&D Center in Chengdu, Sichuan, China. These R&D centers collaborate closely to advance innovative therapies from early discovery to clinical application, ensuring that the company’s drug development remains robust, efficient, and aligned with global healthcare demands. Biokin Pharmaceutical owns four production bases: Guorui Pharmaceutical (injectables and oral formulations), Biokin Pharmaceutical (oral solid dosage forms and lyophilized powder for injection), Haiyate/Jingxi Pharmaceutical (intermediates and chemical active pharmaceutical ingredients), and Duote Bio (innovative drugs).